Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562155 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
A Phase 2 study of Refractory and/or Unexplained Chronic Cough, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT04562155 is a Phase 2 study of Refractory and/or Unexplained Chronic Cough that has completed, run by Bayer. The registered enrollment target is 310 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04562155, a Phase 2 study of Refractory and/or Unexplained Chronic Cough, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC). Study drug BAY1817080 is a new drug under development for the treatment of long-standing cough. It blocks proteins that are expressed by the airway sensory nerves which are oversensitive in patients with long-standing cough. This prevents the urge to cough. Researchers also want to learn the safety of the study drug and how well it works in reducing the cough frequency, severity and urge-to-cough. Participants in this study will receive either the study drug or placebo (a placebo looks like the test drug but does not have any medicine in it) tablets twice daily for 12 weeks. Observation for each participant will last about 18 weeks in total. Participants will be asked to wear a digital device to record the cough and to complete questionnaires every day to document the symptoms. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BAY1817080
Study Locations (20)
Ciudad Auton. de Buenos Aires
- Centro Médico Dra. De Salvo - Clinical Research Center - Buenos Aires
- Centro de Investigaciones Clínicas - CABA
- Fundación CIDEA - CABA
- Investigación en Alergias y Enfermedades Respiratorias-INAER - CABA
New South Wales
- Macquarie University Hospital - Macquarie University
- Maroubra Medical Centre - Maroubra
- Holdsworth House Medical Practice - Sydney
Buenos Aires
- Instituto Ave Pulmo - Mar del Plata
- Centro Respiratorio Quilmes - Quilmes
California
- California Allergy & Asthma Medical Group & Research Center - Los Angeles
Florida
- Florida Pediatrics - Largo
Maryland
- Chesapeake Clinical Research, Inc. - White Marsh
Minnesota
- Minnesota Lung Center - Edina
Montana
- Montana Medical Research, Inc - Missoula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2021-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04562155
The ClinicalTrials.gov registry entry for NCT04562155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory and/or Unexplained Chronic Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04562155 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ciudad Auton. de Buenos Aires, New South Wales, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT04562155 about?
NCT04562155 is a clinical study titled "Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough". Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC). Study drug BAY1817080 is a new drug under development for the treatment of long-standing coug...
What is the current status of trial NCT04562155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2020-10-02. Estimated completion is 2021-07-23.
What conditions does trial NCT04562155 study?
This clinical trial studies the following conditions: Refractory and/or Unexplained Chronic Cough.
What interventions are being tested in trial NCT04562155?
The interventions under investigation include: Placebo (DRUG), BAY1817080 (DRUG).
Who is sponsoring clinical trial NCT04562155?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04562155 being conducted?
This trial has 20 study locations across California, Florida, Maryland, Minnesota, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.